Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
vision restoration
Biotech
Editas claims proof of concept in vision loss gene-editing
Editas has confirmed safety—and its concept—in a small group of patients who have received the gene-editing therapy EDIT-101.
Annalee Armstrong
Sep 29, 2021 9:00am
Visus raises $20M ahead of data drop on rival to AbbVie prospect
Aug 10, 2021 9:10am
BioMarin's gene therapy lead jumps ship to rival biotech Vedere
Jun 22, 2021 8:45am
Mutation-agnostic gene therapy triggers partial vision recovery
May 25, 2021 8:10am
Heru sets sights on virtual reality eye tests with $30M round
May 21, 2021 11:00am
J&J tackles childhood myopia with new FDA contact lens clearance
May 12, 2021 12:32pm
